Published On: Wed, Sep 25th, 2013

Access Pharmaceuticals, Inc. (OTCBB: ACCP) Announces MuGard Poster Presentation At ASTRO Conference

Access Pharmaceuticals, Inc. (OTCBB: ACCP), an emerging biopharmaceutical company, announced Tuesday, September 24th a poster presentation at the American Society for Radiation Oncology Meeting, September 22-25, 2013, in Atlanta, GA.

Dr. David Nowotnik stated in the company’s press release dated September 24th,  “The impact of mucositis on patients is significant with particular affect on their ability to eat and maintain their weight. Due to the oral pain and discomfort of OM, patients eat less and lose weight as a result. Previous studies have shown that severe weight loss during chemoradiation therapy correlates with lower quality of life after therapy and a higher risk of mortality.”

The poster presentation has been co-authored by Access Pharmaceuticals’ Senior Vice President Research and Development, Dr. David Nowotnik, entitled, “Results from the Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of MuGard in Mitigating Oral Mucositis (OM) in Chemoradiation-Treated Head and Neck Cancer Patients.”   The presentation is expected to discuss the findings from the Company’s post-marketing clinical trial.

The clinical trial evaluated the efficacy of MuGard in controlling symptoms caused by oral mucositis in 120 patients receiving chemoradiation therapy for the treatment of cancers of the head and neck.

© Copyright 2016 OTC News Magazine. All rights reserved.